X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9075) 9075
Publication (899) 899
Book Review (100) 100
Book Chapter (62) 62
Conference Proceeding (29) 29
Dissertation (13) 13
Paper (5) 5
Book / eBook (3) 3
Magazine Article (3) 3
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5657) 5657
index medicus (4487) 4487
animals (3417) 3417
male (2762) 2762
female (2157) 2157
diabetes mellitus, type 2 - drug therapy (2100) 2100
dipeptidyl peptidase 4 - metabolism (1779) 1779
type 2 diabetes (1621) 1621
endocrinology & metabolism (1596) 1596
dipeptidyl-peptidase iv inhibitors - therapeutic use (1485) 1485
diabetes (1426) 1426
middle aged (1413) 1413
glucagon-like peptide-1 (1294) 1294
hypoglycemic agents - therapeutic use (1293) 1293
rats (1242) 1242
mice (1222) 1222
biochemistry & molecular biology (1166) 1166
pharmacology & pharmacy (1097) 1097
aged (1063) 1063
adult (1057) 1057
dipeptidyl peptidase 4 (961) 961
dipeptidyl-peptidase iv inhibitors - pharmacology (902) 902
sitagliptin (899) 899
glucose (862) 862
analysis (815) 815
dipeptidyl peptidase-4 inhibitor (813) 813
expression (761) 761
dipeptidyl peptidase-iv (696) 696
treatment outcome (693) 693
diabetes mellitus, type 2 - blood (681) 681
research (675) 675
insulin (674) 674
dipeptidyl-peptidases and tripeptidyl-peptidases - metabolism (660) 660
dipeptidyl peptidase iv (649) 649
diabetes mellitus (643) 643
metformin (637) 637
hypoglycemic agents (621) 621
glycemic control (618) 618
dipeptidyl-peptidase iv inhibitors - adverse effects (611) 611
double-blind (611) 611
blood glucose - metabolism (608) 608
cell biology (588) 588
cd26 (583) 583
adamantane - analogs & derivatives (580) 580
care and treatment (577) 577
peptidase (575) 575
immunology (559) 559
peptides (553) 553
dipeptidyl-peptidase-iv (551) 551
amino acid sequence (538) 538
molecular sequence data (529) 529
hypoglycemic agents - adverse effects (528) 528
dipeptidyl peptidase 4 - genetics (506) 506
hypoglycemic agents - pharmacology (506) 506
vildagliptin (505) 505
proteins (499) 499
enzymes (496) 496
dipeptidyl peptidase-4 inhibitors (493) 493
drug therapy, combination (490) 490
sitagliptin phosphate (486) 486
blood glucose - drug effects (482) 482
internal medicine (476) 476
risk factors (470) 470
dipeptidyl-peptidase iv inhibitors - administration & dosage (466) 466
type-2 diabetes-mellitus (453) 453
type 2 diabetes mellitus (448) 448
drug therapy (443) 443
glp-1 (438) 438
hypoglycemic agents - administration & dosage (432) 432
dextrose (430) 430
physiological aspects (426) 426
safety (425) 425
proteases (424) 424
glucagon (423) 423
diabetes therapy (415) 415
dipeptidyl peptidase 4 - blood (413) 413
health aspects (409) 409
medicine, research & experimental (399) 399
efficacy (389) 389
beta-cell function (385) 385
inhibitors (378) 378
chemistry, medicinal (375) 375
dipeptidyl peptidase 4 - chemistry (375) 375
medicine & public health (375) 375
diabetes mellitus, type 2 - complications (369) 369
inflammation (368) 368
article (360) 360
cells, cultured (360) 360
dpp-4 inhibitor (359) 359
diabetes mellitus, type 2 - metabolism (358) 358
kinetics (352) 352
medicine, general & internal (352) 352
glycated hemoglobin a - metabolism (350) 350
mice, inbred c57bl (348) 348
metformin - therapeutic use (347) 347
dipeptidyl-peptidase iv inhibitors (346) 346
insulin resistance (345) 345
time factors (339) 339
mellitus (338) 338
dose-response relationship, drug (328) 328
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8844) 8844
German (71) 71
Japanese (47) 47
Spanish (30) 30
Chinese (25) 25
Korean (24) 24
French (18) 18
Russian (18) 18
Czech (15) 15
Polish (7) 7
Portuguese (5) 5
Hungarian (3) 3
Dutch (2) 2
Norwegian (2) 2
Turkish (2) 2
Croatian (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2013, Volume 495, Issue 7440, pp. 251 - 254
Journal Article
Journal Article
Journal Article
American Journal of Pathology, ISSN 0002-9440, 01/2016, Volume 186, Issue 1, pp. 78 - 86
Dipeptidyl peptidase 4 (DPP4, CD26), a type II transmembrane ectopeptidase, is the receptor for the Middle Eastern respiratory syndrome coronavirus (MERS-CoV).... 
DROMEDARY CAMELS | IN-VITRO | DPP-IV | DENDRITIC CELLS | AMINOPEPTIDASE N | MOUSE MODEL | CORONAVIRUS MERS-COV | CLINICAL-ASPECTS | INFECTION | PATHOLOGY | EXPRESSION | Immunohistochemistry | Coronavirus Infections | Dipeptidyl Peptidase 4 - biosynthesis | Humans | Middle Aged | Child, Preschool | Infant | Male | Respiratory System - enzymology | Young Adult | Adolescent | Adult | Female | Aged | Child | Regular
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 11/2011, Volume 124, Issue 21, pp. 2338 - 2349
Background-Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasingly used to accomplish glycemic targets in patients with type II diabetes mellitus. Because... 
adenosine | atherosclerosis | nitric oxide | diabetes mellitus | monocyte chemoattractant proteins | inflammation | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | ADENOSINE-DEAMINASE | DIET-INDUCED OBESITY | GLUCAGON-LIKE PEPTIDE-1 | HUMAN CD26 | INSULIN-RESISTANCE | PERIPHERAL VASCULAR DISEASE | INDEPENDENT PATHWAYS | GLUCOSE-UPTAKE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | T-CELLS | Inflammation - pathology | Apolipoproteins E - deficiency | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Male | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Cell Movement - physiology | Uracil - pharmacology | Chemotaxis - physiology | Piperidines - pharmacology | Time Factors | Insulin Resistance - physiology | Metabolism - drug effects | Monocytes - pathology | Receptors, LDL - deficiency | Blood Pressure - drug effects | Disease Models, Animal | Receptors, LDL - genetics | Atherosclerosis - pathology | Atherosclerosis - physiopathology | Uracil - therapeutic use | Chemotaxis - drug effects | Mice, Knockout | Animals | Piperidines - therapeutic use | Apolipoproteins E - genetics | Glucose - metabolism | Inflammation - prevention & control | Mice | Atherosclerosis - prevention & control | Inflammation - physiopathology | Uracil - analogs & derivatives | Care and treatment | Enzyme inhibitors | Research | Proteases | Atherosclerosis
Journal Article
Cardiovascular Research, ISSN 0008-6363, 10/2012, Volume 96, Issue 1, pp. 140 - 149
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 333 - 347
Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycaemic control over the long... 
linagliptin | glyburide | incretin | saxagliptin | diabetes mellitus | omarigliptin | anagliptin | gliclazide | glimepiride | sitagliptin | vildagliptin | gemigliptin | alogliptin | antidiabetic drug | glipizide | glycaemic control | trelagliptin | GLP‐1 | glibenclamide | evogliptin | teneligliptin | Glimepiride | Incretin | GLP-1 | Trelagliptin | Diabetes mellitus | Sitagliptin | Glipizide | Evogliptin | Anagliptin | Glyburide | Antidiabetic drug | Omarigliptin | Gliclazide | Alogliptin | Linagliptin | Vildagliptin | Gemigliptin | Glibenclamide | Glycaemic control | Teneligliptin | Saxagliptin | SEVERE HYPOGLYCEMIA | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS | INSULIN SECRETAGOGUES | GLYCEMIC CONTROL | CARDIOVASCULAR EVENTS | DPP-4 INHIBITOR | DOUBLE-BLIND | METFORMIN THERAPY | SAVOR-TIMI 53 | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Risk | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Weight Gain - drug effects | Sulfonylurea Compounds - administration & dosage | Diabetic Angiopathies - prevention & control | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Diabetic Cardiomyopathies - epidemiology | Diabetic Angiopathies - epidemiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Prescription drugs | Insulin | Side effects | Peptidase | Clinical trials | Metformin | Hypoglycemia | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Patients
Journal Article
Atherosclerosis, ISSN 0021-9150, 2012, Volume 226, Issue 2, pp. 305 - 314
Journal Article